dc.contributor.author | Ortiz Arduán, Alberto | |
dc.contributor.author | Sánchez Niño, María Dolores | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) | es_ES |
dc.date.accessioned | 2020-06-05T08:24:17Z | |
dc.date.available | 2020-06-05T08:24:17Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Clinical Kidney Journal 12.1 (2019): 110-112 | en_US |
dc.identifier.issn | 2048-8505 (print) | en_US |
dc.identifier.issn | 2048-8513 (online) | en_US |
dc.identifier.uri | http://hdl.handle.net/10486/691191 | |
dc.description.abstract | Sarcopenia and frailty are recognized as key risk factors for adverse outcomes in patients on renal replacement therapy or
with non-dialysis chronic kidney disease (CKD). However, there is still debate about their pathogenesis and, thus, about the
best therapeutic approaches, as well as the impact on outcomes of current approaches based on different exercise
programmes. In the past two issues of Clinical Kidney Journal, several manuscripts address the issue of sarcopenia in CKD
from the point of view of pathogenesis and new therapeutic approaches, monitoring of results, implementation of exercise
programmes and specific potential benefits of exercise programmes in dialysis and non-dialysis CKD patients, as assessed by clinical trials | en_US |
dc.format.extent | 3 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | Oxford University Press | en_US |
dc.relation.ispartof | Clinical Kidney Journal | en_US |
dc.subject.other | Chronic kidney disease | en_US |
dc.subject.other | Exercise | en_US |
dc.subject.other | Frailty | en_US |
dc.subject.other | Inflammation | en_US |
dc.subject.other | Rotein-energy wasting | en_US |
dc.subject.other | Sarcopenia | en_US |
dc.subject.other | Satellite cell | en_US |
dc.subject.other | TWEAK | en_US |
dc.subject.other | Osteosarcopenia | en_US |
dc.title | Sarcopenia in CKD: A roadmap from basic pathogenetic mechanisms to clinical trials | en_US |
dc.type | other | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | https://doi.org/10.1093/ckj/sfz001 | es_ES |
dc.identifier.doi | 10.1093/ckj/sfz001 | es_ES |
dc.identifier.publicationfirstpage | 110 | es_ES |
dc.identifier.publicationissue | 1 | es_ES |
dc.identifier.publicationlastpage | 112 | es_ES |
dc.identifier.publicationvolume | 12 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento – NoComercial | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Ortiz Arduan, Alberto (261886) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD) | |